P2, N=20, Recruiting, Gottfried von Keudell, MD PhD | Not yet recruiting --> Recruiting

P2, N=30, Not yet recruiting, University of Washington

We analyzed 125 patients with the following characteristics: median age, 61 years (55; 67), advanced-stage disease, 88.8%; high FLIPI, 49.6%; TMTV, > 510 cm3; B2M, > 3 mg/L (24.8%); and R-CHOP-like treatment, 86.4%...Patients at intermediate and high risk according to the TMTV/B2M score were at high risk of disease progression within 24 months of treatment initiation (HR = 2.45 [95% CI: 1.23-4.85] and HR = 3.75 [95% CI: 1.7-8.2], respectively). This TMTV/B2M score may identify patients with the highest unmet medical needs.

P2, N=3, Active, not recruiting, M.D. Anderson Cancer Center | N=24 --> 3 | Trial completion date: Jun 2024 --> Dec 2025

P2, N=30, Recruiting, Columbia University | Trial completion date: May 2025 --> Feb 2026 | Trial primary completion date: May 2024 --> Feb 2025

P=N/A, N=100, Active, not recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna

P2, N=76, Active, not recruiting, Seoul National University Hospital | Recruiting --> Active, not recruiting

P1, N=23, Not yet recruiting, City of Hope Medical Center

P1/2, N=65, Recruiting, Hoffmann-La Roche | Trial primary completion date: Oct 2027 --> Mar 2027

P1/2, N=237, Recruiting, Hoffmann-La Roche | Trial completion date: Nov 2027 --> Oct 2030 | Trial primary completion date: Nov 2025 --> Oct 2028

In this study, we further developed our protocol MCCS-Docker for protein-protein interactions and applied it to investigate the structural intricacies of CD3 interactions with therapeutic antibodies such as OKT3, UCHT1, Mosunetuzumab, Odronextumab, Glofitamab, and Epcoritamab using computational modeling techniques. Molecular dynamics simulations validated the stability of these interactions over time, confirming the reliability of the binding poses generated from docking studies. Overall, our study offered a novel method to predict critical residues in protein-protein interactions and enhanced the understanding of the structural determinants governing BsAb interactions with target proteins, offering valuable insights for designing and optimizing immunotherapeutic agents for NHL and related hematologic malignancies.

P1/2, N=38, Completed, Prof. Dr. Clemens Schmitt | Active, not recruiting --> Completed | Trial primary completion date: Jun 2024 --> Nov 2024

P1, N=121, Recruiting, Hoffmann-La Roche | Trial completion date: Jul 2028 --> Mar 2029 | Trial primary completion date: Jul 2026 --> Mar 2027

Consequently, she was treated with rituximab for PMZL, with plans to address the adenocarcinoma through stereotactic body radiation therapy (SBRT)...While a direct correlation between chronic inflammation, frequent infectious pathogens, and the development of PMZL has yet to be established, a known association exists between EMZL and pathogens such as Helicobacter pylori in gastric involvement and Chlamydia psittaci in ocular adnexa. This report highlights the difficulties in obtaining a diagnosis for PMZL and examines the various mechanisms that may have contributed to this unusual finding.

P1/2, N=543, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

P1, N=25, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

P2, N=12, Completed, Bnai Zion Medical Center | Active, not recruiting --> Completed

P2, N=360, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P2, N=120, Active, not recruiting, University Hospital Tuebingen | Recruiting --> Active, not recruiting

P3, N=171, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P2, N=34, Not yet recruiting, Northwestern University

P2, N=141, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Jul 2025 --> Nov 2025

P3, N=128, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Dec 2027 --> Aug 2027

AVO was highly active and well-tolerated in patients with previously untreated CLL with high-risk CLL, supporting its use as a new standard of care treatment option.

Treatment included R-CHOP (n=26), R-DA EPOCH (n=2), MTR (n=1), and R-MPV (n=1).26.66% had PD-L1 <1% while 73.33% had PD-L1 ≥1%; 33.33% had PD-L1 <5%, while 66.67% had PD-L1 ≥5%...Limitations include small number of patients, short follow up and inclusion of 2 patients of primary CNS lymphoma, that might have affected the analysis minimally. Further research is essential to standardize the cutoff value and scoring method.

Uni- and multi-variate analyses of clinical variables that may be associated with clinical and MRD outcomes are underway.Conclusions : Bendamustine, rituximab and acalabrutinib front-line therapy for WM is safe and well tolerated in a relatively elderly population with a toxicity profile consistent with the utilized drugs and not greater than that seen with BR and Placebo in the randomized ECHO trial in untreated Mantle Cell Lymphoma. Initial clinical results show that this treatment is associated with a very high proportion of CR + VGPRs as well as MRD negativity.

While 12-month PFS failed to reach statistical significance, subgroup analyses favor Pola-R-CHP. Further research with a wider population, longer follow-up, and screening of advantageous groups are warranted.

This is an analysis of 127 patients with HIV with Burkitt lymphoma (HIV-BL) and diffuse large B-cell lymphoma (HIV-DLBCL) treated at the Zhongnan Hospital of Wuhan University over a 17-year period during the ART and rituximab era...Current China practice favours the treatment of HIV-BL and HIV-DLBCL similarly to the HIV-negative population with the use of concurrent ART. However, due to the extremely low percentage of patients receiving ART prior to the lymphoma diagnosis, the high percentage of patients with poor performance status, and the advanced stage at diagnosis, the treatment of HIV-related lymphoma remains the major challenge in China.

P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2027

Adjuvant R-CVP and elevated intratumoural CD8 expression were independently associated with sustained disease control after radiotherapy in ESFL.

These findings were suggestive of interdigitating dendritic cell sarcoma (IDCS). Systemic chemotherapy with R-CHOP was initiated and after the first 4 cycles of treatment, retroperitoneal adenopathies regressed, with stability of metastatic liver disease.

P3, N=100, Recruiting, Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)

P2, N=26, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: May 2026 --> Feb 2027

P3, N=500, Recruiting, Genmab | Trial completion date: Jun 2030 --> Oct 2030 | Trial primary completion date: Nov 2029 --> Oct 2030

P3, N=900, Recruiting, Genmab | Trial primary completion date: Sep 2028 --> Jun 2027

P2, N=184, Recruiting, Genmab | Trial completion date: May 2029 --> Mar 2027 | Trial primary completion date: May 2029 --> Mar 2027

P1/2, N=860, Recruiting, Hoffmann-La Roche | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026

P1, N=137, Recruiting, Hoffmann-La Roche | Trial primary completion date: May 2027 --> Aug 2027

P3, N=1080, Recruiting, Genmab | Trial completion date: May 2037 --> Nov 2037 | Trial primary completion date: May 2037 --> Nov 2037

P2, N=622, Recruiting, Genmab | Trial completion date: Nov 2032 --> Jun 2031 | Trial primary completion date: Nov 2032 --> Jun 2031

At present, studies at home and abroad have confirmed that the 90-minute short duration infusion of obinutuzumab is safe and feasible.In order to improve the convenience of patient infusion and the efficiency of medical institutions'infusion facilities, it is recommended for patients who do not experience grade ≥3 infusion-related adverse reactions in the first cycle of obinutuzumab infusion at the standard rate, a short duration infusion scheme should be used for subsequent treatment courses. This expert consensus is formulated to provide guidance for clinical practice.

P=N/A, N=111, Not yet recruiting, Region Stockholm